Mushroom Therapy: Healing Power Of Psychedelics

Psilocybin, the primary psychoactive ingredient in magic mushrooms, has been used as a recreational drug and was associated with 1960s counterculture. However, research over the past 20 years has shown that psilocybin has significant potential in treating mental and behavioral health disorders, such as depression, anxiety, eating disorders, PTSD, and addiction. The U.S. Food and Drug Administration (FDA) has recognized this potential by granting breakthrough therapy designation to psilocybin-assisted psychotherapy for major depressive disorder and treatment-resistant depression. During psilocybin-assisted therapy, patients may wear eye shades, listen to music, and be guided by trained medical staff over the course of several hours. While psilocybin therapy shows promise, it has not yet been approved by the FDA and further clinical trials are needed to understand how it works, who it works for, and when and how often it should be used.

Psilocybin is the active ingredient in magic mushrooms

Psilocybin is the primary psychoactive ingredient in "magic mushrooms". It is a fungal metabolite naturally found in a multitude of mushroom species. Psilocybin was first isolated from a sample of dried Psilocybe mexicana mushrooms by Albert Hofmann, a chemist at the Swiss company Sandoz Pharmaceuticals. Hofmann identified psilocybin as the psychedelic compound in the mushrooms, and the company began manufacturing and distributing a pill containing psilocybin for use in psychiatric research.

Psilocybin is a powerful psychedelic compound, capable of altering perception of space and time, causing visual distortions, euphoria, and mystical experiences. It interacts with serotonin receptors in the brain, specifically 2A and 2C, enhancing sensory input and creating hallucinations and a strong sense of connection. This can lead to a phenomenon called synesthesia, where senses are crossed, resulting in experiences such as seeing sounds or hearing colours.

Research has shown that psilocybin has significant potential in the treatment of various psychiatric and behavioural health disorders. Studies suggest that when administered in controlled conditions with supportive therapy, psilocybin may be useful for treating depression, anxiety, addiction, and existential distress caused by serious illnesses. For example, a Johns Hopkins study found that taking psilocybin in combination with talk therapy improved symptoms of clinical depression, with some participants experiencing benefits for up to a year after only two doses.

Despite the potential therapeutic benefits of psilocybin, it is important to approach it with caution. Psilocybin can cause death at very high doses, and some poisonous mushrooms resemble psilocybin-containing mushrooms, leading to potential fatal poisoning. Additionally, psilocybin is currently classified as a Schedule I controlled substance, indicating it has "no currently accepted medical use and a high potential for abuse". However, there is a growing interest in researching the therapeutic potential of psilocybin, and states like Colorado and Oregon have already legalized its therapeutic use.

Research suggests psilocybin can treat mental health disorders

Psilocybin, the active ingredient in "magic mushrooms", is a powerful psychedelic. It is capable of altering perception of space and time, causing visual distortions, euphoria, and mystical experiences. Psilocybin interacts with serotonin receptors in the brain to trigger various psychedelic effects.

Research suggests that psilocybin may be useful in treating various psychiatric and behavioural disorders. For example, psilocybin has shown potential in treating depression. A study by Johns Hopkins Medicine found that taking psilocybin in combination with talk therapy significantly improved symptoms of clinical depression. Some study participants continued to experience benefits for as long as one year after receiving just two doses. Another randomized, double-blind trial from Johns Hopkins in 2016 found that a single dose of psilocybin substantially improved quality of life and decreased depression and anxiety in people with life-threatening cancer diagnoses. The U.S. Food and Drug Administration (FDA) granted “breakthrough therapy” designation to psilocybin-assisted psychotherapy for major depressive disorder in 2019.

Psilocybin has also shown positive results in treating addiction. A 2022 study compared the effect of psychotherapy plus two psilocybin sessions to psychotherapy plus a placebo in 93 people with moderate alcohol use disorder. Participants who received the psilocybin-assisted psychotherapy had fewer heavy drinking days over 32 weeks, suggesting that psilocybin may be helpful for alcohol use disorder. Researchers in Alabama are also currently conducting trials for psilocybin therapy on cocaine addiction.

Psilocybin has also been studied for its potential in treating anxiety and existential distress in people with advanced-stage cancer. A pilot study in 2011 on psilocybin treatment for anxiety in people with cancer found promising preliminary results.

Despite the potential benefits of psilocybin, it is important to note that it is currently classified as a Schedule I controlled substance by the federal government, indicating that it has "no currently accepted medical use and a high potential for abuse". However, states like Colorado and Oregon have legalized therapeutic psilocybin use. Researchers are forging ahead with clinical trials in pursuit of FDA approval.

Psilocybin therapy must be administered in controlled settings

Psilocybin, the active ingredient in "magic mushrooms", is a powerful psychedelic compound that has attracted growing interest from researchers for its potential therapeutic benefits. Despite its promise, psilocybin therapy must be approached with caution and administered in controlled settings for several reasons.

Firstly, psilocybin can cause death at very high doses. Additionally, some poisonous mushrooms resemble psilocybin-containing mushrooms, and confusing the two could lead to fatal poisoning. Therefore, it is crucial that psilocybin therapy is administered in a controlled setting where trained professionals can ensure the accurate identification and dosage of psilocybin mushrooms.

Secondly, psilocybin can induce psychologically challenging situations, sometimes referred to as a "bad trip". These can include delirium, panic attacks, depersonalisation, extreme distress, and symptoms resembling schizophrenia. Trained therapists in a controlled setting can help manage the "set" (the mental state with which the participant enters the experience) and "setting" (the physical environment, support staff, music, etc.) to enhance safety and mitigate the risk of adverse psychological reactions.

Furthermore, psilocybin therapy often involves weeks of therapy leading up to and following the administration of psilocybin. This preparatory and integrative therapy is an essential aspect of the treatment process and requires a controlled setting with trained therapists to facilitate effective and safe outcomes.

The controlled setting also enables researchers and therapists to minimise variables and better understand the impact of non-pharmacological factors on treatment outcomes. By controlling the environment, therapists can tailor the setting to individual patient needs, thereby optimising the therapeutic experience.

In conclusion, while psilocybin therapy shows promise for treating various psychiatric and behavioural disorders, it must be administered in controlled settings with appropriate therapeutic support to ensure patient safety and maximise therapeutic efficacy.

Psilocybin therapy is not FDA-approved

Psilocybin, the active ingredient in "magic mushrooms", is a powerful psychedelic. It is capable of altering perception and causing visual distortions, euphoria, and mystical experiences. Psilocybin therapy has been used to treat a range of psychiatric and behavioral disorders, including depression, anxiety, and addiction. However, it is important to note that psilocybin therapy is not currently FDA-approved.

While psilocybin has shown potential in treating various mental health conditions, it has not yet received approval from the FDA for any specific indication. The FDA is the agency responsible for evaluating and approving drugs for medical use in the United States, ensuring their safety and effectiveness. In recent years, there has been growing interest in the therapeutic potential of psychedelic drugs, including psilocybin. The FDA has recognized this interest and published draft guidance for researchers conducting clinical trials on psychedelic drugs.

The FDA's draft guidance outlines the unique challenges inherent in designing clinical studies for psychedelic drugs and provides recommendations for addressing these challenges. The goal is to assist researchers in conducting rigorous and well-controlled trials that can effectively evaluate the safety and efficacy of psilocybin therapy. While the FDA has granted "breakthrough therapy" designation to psilocybin-assisted psychotherapy for major depressive disorder and treatment-resistant depression, this is not the same as FDA approval.

The lack of FDA approval for psilocybin therapy means that it is not yet widely available as a mainstream treatment option. It also indicates that the therapy's safety and effectiveness have not been conclusively established to the FDA's standards. However, this does not mean that psilocybin therapy is completely inaccessible. In states like Colorado and Oregon, therapeutic psilocybin use has been legalized, and it can be administered under the care of a trained therapist or facilitator.

It is important to note that psilocybin can be dangerous at very high doses and that some poisonous mushrooms resemble psilocybin-containing mushrooms. Therefore, individuals should not attempt to self-medicate with psilocybin mushrooms without proper guidance and supervision. As research progresses and more clinical trials are conducted, psilocybin therapy may move closer to obtaining FDA approval and becoming a widely accepted treatment modality.

Psilocybin therapy is expensive

The cost of psilocybin-assisted therapy is influenced by various factors, including the need for a trained therapist or facilitator, the physical environment and support staff, and the safety precautions that must be in place due to the risks associated with psychedelic substances. The synthetic production of psilocybin is also complicated and expensive, further contributing to the overall cost of therapy.

Additionally, psilocybin therapy faces regulatory hurdles and stigma, which impact funding opportunities and, consequently, the affordability of treatment. The classification of psilocybin mushrooms as Schedule I drugs, indicating no accepted medical use and a high potential for abuse, has created legal barriers that hinder research and development. This classification, along with the historical connotations associated with psilocybin, has led to stigmatization and reduced governmental funding for projects involving this compound.

The high cost of psilocybin therapy limits its accessibility, as many individuals who could potentially benefit from the treatment may lack the financial resources to afford it. This disparity in access based on socioeconomic status is a critical concern, as it may prevent those with conditions such as post-traumatic stress disorder, postpartum depression, treatment-resistant depression, and alcohol use disorder from receiving effective treatment.

While at-home use of psychedelics may be a more affordable option, it also raises concerns about effectiveness, safety, and potential abuse. Experts worry that without the guidance of a trained clinician, individuals may be at risk of traumatic injuries or incorrect dosage, especially with substances like ketamine. Therefore, the decision between costly psychedelic-assisted therapy and at-home use presents a challenging dilemma for patients.

Frequently asked questions